REGN logo

REGN EBITDA

Annual EBITDA

$5.32 B
+$624.70 M+13.31%

December 31, 2024

Summary

Performance

1-Year Change

+13.31%

3-Year Change

-45%

5-Year Change

+99.21%

15-Year Change

+136.45%

REGN EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

98.06%
REGN annual EBITDA is higher than 98.06% of companies in Healthcare sector

High & Low

All-time High

$9.67 B
REGN annual EBITDA is currently -45.00% below its historical high of $9.67 billion

3-Year Low

$4.69 B
REGN annual EBITDA is currently +13.31% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
REGN previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
REGN next annual earnings announcement has not yet been scheduled

OtherREGNprofitabilitymetrics:

Annual Revenue

$14.20 B
REGN annual revenue is $14.20 billion

Annual Net Income

$4.41 B
REGN annual net profit is $4.41 billion

Annual EBIT

$4.84 B
REGN annual earnings before interest & taxes is $4.84 billion

Annual EPS

$38.34
REGN annual earnings per share is $38.34

Quarterly EBITDA

$1.09 B
-$533.50 M-32.76%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

-14.38%

3-Year Change

-14.38%

5-Year Change

-14.38%

REGN Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

97.87%
REGN quarterly EBITDA is higher than 97.87% of companies in Healthcare sector

High & Low

All-time High

$3.84 B
REGN quarterly EBITDA is currently -71.47% below its historical high of $3.84 billion

3-Year Low

$830.90 M
REGN quarterly EBITDA is currently +31.78% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
REGN previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 2, 2025
REGN next earnings announcement is scheduled for May 2, 2025

OtherREGNprofitabilitymetrics:

Quarterly Revenue

$3.79 B
REGN quarterly revenue is $3.79 billion

Quarterly Net Income

$917.70 M
REGN quarterly net profit is $917.70 million

Quarterly EBIT

$968.60 M
REGN quarterly earnings before interest & taxes is $968.60 million

Quarterly EPS

$8.06
REGN quarterly earnings per share is $8.06

TTM EBITDA

$5.32 B
-$183.90 M-3.34%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+13.31%

3-Year Change

+13.31%

5-Year Change

+13.31%

REGN TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

97.95%
REGN TTM EBITDA is higher than 97.95% of companies in Healthcare sector

High & Low

All-time High

$9.67 B
REGN TTM EBITDA is currently -45.00% below its historical high of $9.67 billion

3-Year Low

$4.55 B
REGN TTM EBITDA is currently +16.91% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
REGN previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 2, 2025
REGN next earnings announcement is scheduled for May 2, 2025

OtherREGNprofitabilitymetrics:

TTM Revenue

$14.20 B
REGN TTM revenue is $14.20 billion

TTM Net Income

$4.41 B
REGN TTM net profit is $4.41 billion

TTM EBIT

$4.84 B
REGN TTM earnings before interest & taxes is $4.84 billion

TTM EPS

$38.28
REGN TTM earnings per share is $38.28

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

$5.32 B
REGN annual EBITDA is $5.32 billion

Annual Net Income

$4.41 B
REGN annual net profit is $4.41 billion

Annual Interest Expense

$55.20 M
REGN annual interest expense is $55.20 million

Annual Income Tax

$367.30 M
REGN annual income tax is $367.30 million

Annual D&A

$482.90 M
REGN annual depreciation & amortization is $482.90 million

REGN EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+13.3%-14.4%+13.3%
3 y3 years-45.0%-14.4%+13.3%
5 y5 years+99.2%-14.4%+13.3%

REGN EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-45.0%+13.3%-57.8%+31.8%-45.0%+16.9%
5 y5-year-45.0%+99.2%-71.5%+49.8%-45.0%+99.2%
alltimeall time-45.0%+3218.6%-71.5%+2229.6%-45.0%+3218.6%

Regeneron Pharmaceuticals EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
$5.32 B(+13.3%)
$1.09 B(-32.8%)
$5.32 B(-3.3%)
Sep 2024
-
$1.63 B(-7.7%)
$5.50 B(+7.7%)
Jun 2024
-
$1.76 B(+112.3%)
$5.11 B(+12.3%)
Mar 2024
-
$830.90 M(-35.0%)
$4.55 B(-3.1%)
Dec 2023
$4.69 B(-10.8%)
$1.28 B(+3.6%)
$4.69 B(-3.4%)
Sep 2023
-
$1.23 B(+2.4%)
$4.86 B(-7.3%)
Jun 2023
-
$1.20 B(+23.5%)
$5.24 B(+3.0%)
Mar 2023
-
$975.50 M(-32.4%)
$5.09 B(-3.3%)
Dec 2022
$5.26 B(-45.6%)
$1.44 B(-10.8%)
$5.26 B(-17.9%)
Sep 2022
-
$1.62 B(+54.0%)
$6.41 B(-4.3%)
Jun 2022
-
$1.05 B(-8.6%)
$6.70 B(-29.4%)
Mar 2022
-
$1.15 B(-55.7%)
$9.48 B(-1.9%)
Dec 2021
$9.67 B(+135.7%)
$2.59 B(+36.1%)
$9.67 B(+15.4%)
Sep 2021
-
$1.90 B(-50.4%)
$8.38 B(+10.9%)
Jun 2021
-
$3.84 B(+187.5%)
$7.56 B(+60.6%)
Mar 2021
-
$1.33 B(+2.6%)
$4.71 B(+14.7%)
Dec 2020
$4.10 B(+53.7%)
$1.30 B(+20.0%)
$4.10 B(+9.3%)
Sep 2020
-
$1.08 B(+9.8%)
$3.75 B(+7.3%)
Jun 2020
-
$987.40 M(+35.1%)
$3.50 B(+25.1%)
Mar 2020
-
$730.80 M(-23.1%)
$2.80 B(+4.7%)
Dec 2019
$2.67 B(-2.2%)
$950.80 M(+14.7%)
$2.67 B(+9.2%)
Sep 2019
-
$829.20 M(+191.2%)
$2.45 B(+6.6%)
Jun 2019
-
$284.80 M(-52.9%)
$2.29 B(-15.2%)
Mar 2019
-
$604.80 M(-16.7%)
$2.71 B(-0.9%)
Dec 2018
$2.73 B(+21.4%)
$726.40 M(+7.0%)
$2.73 B(+5.0%)
Sep 2018
-
$678.70 M(-2.6%)
$2.60 B(+2.7%)
Jun 2018
-
$696.60 M(+10.9%)
$2.53 B(+5.4%)
Mar 2018
-
$628.20 M(+5.5%)
$2.40 B(+6.7%)
Dec 2017
$2.25 B(+56.0%)
$595.31 M(-2.3%)
$2.25 B(+11.0%)
Sep 2017
-
$609.51 M(+7.6%)
$2.03 B(+11.9%)
Jun 2017
-
$566.38 M(+18.5%)
$1.81 B(+15.8%)
Mar 2017
-
$477.90 M(+28.1%)
$1.56 B(+8.5%)
Dec 2016
$1.44 B(+9.7%)
$373.18 M(-5.3%)
$1.44 B(+10.4%)
Sep 2016
-
$394.22 M(+23.8%)
$1.31 B(-1.6%)
Jun 2016
-
$318.54 M(-10.5%)
$1.33 B(-3.2%)
Mar 2016
-
$355.77 M(+49.8%)
$1.37 B(+4.3%)
Dec 2015
$1.31 B(+54.4%)
$237.44 M(-42.8%)
$1.31 B(+2.1%)
Sep 2015
-
$415.24 M(+14.8%)
$1.29 B(+19.5%)
Jun 2015
-
$361.81 M(+20.7%)
$1.08 B(+13.7%)
Mar 2015
-
$299.76 M(+42.6%)
$947.02 M(+11.2%)
Dec 2014
$851.29 M(+8.6%)
$210.21 M(+2.5%)
$851.29 M(+0.7%)
Sep 2014
-
$205.06 M(-11.6%)
$845.21 M(-4.9%)
Jun 2014
-
$232.00 M(+13.7%)
$888.38 M(+7.7%)
Mar 2014
-
$204.03 M(-0.0%)
$825.14 M(+5.2%)
Dec 2013
$784.02 M(+57.9%)
$204.13 M(-17.8%)
$784.02 M(+6.6%)
Sep 2013
-
$248.22 M(+47.1%)
$735.73 M(+5.1%)
Jun 2013
-
$168.76 M(+3.6%)
$699.71 M(+11.4%)
Mar 2013
-
$162.91 M(+4.5%)
$628.35 M(+26.5%)
Dec 2012
$496.67 M(-391.3%)
$155.83 M(-26.6%)
$496.67 M(+63.3%)
Sep 2012
-
$212.21 M(+117.9%)
$304.16 M(+616.0%)
Jun 2012
-
$97.40 M(+211.9%)
$42.48 M(-139.9%)
Mar 2012
-
$31.23 M(-185.1%)
-$106.33 M(-37.6%)
Dec 2011
-$170.53 M(+125.4%)
-$36.68 M(-25.9%)
-$170.53 M(+21.9%)
Sep 2011
-
-$49.47 M(-3.8%)
-$139.90 M(+19.4%)
Jun 2011
-
-$51.42 M(+56.0%)
-$117.19 M(+38.9%)
Mar 2011
-
-$32.97 M(+444.6%)
-$84.37 M(+11.5%)
Dec 2010
-$75.66 M(+36.7%)
-$6.05 M(-77.4%)
-$75.66 M(-24.0%)
Sep 2010
-
-$26.75 M(+43.7%)
-$99.59 M(+41.2%)
Jun 2010
-
-$18.61 M(-23.3%)
-$70.55 M(+8.2%)
Mar 2010
-
-$24.25 M(-19.1%)
-$65.21 M(+21.6%)
Dec 2009
-$55.37 M(-4.1%)
-$29.98 M(-1404.3%)
-$53.62 M(+54.1%)
Sep 2009
-
$2.30 M(-117.3%)
-$34.80 M(-35.9%)
Jun 2009
-
-$13.27 M(+4.8%)
-$54.26 M(-5.9%)
Mar 2009
-
-$12.66 M(+13.4%)
-$57.67 M(-0.5%)
Dec 2008
-$57.74 M(-29.6%)
-$11.17 M(-34.9%)
-$57.97 M(+67.8%)
Sep 2008
-
-$17.16 M(+2.9%)
-$34.54 M(-35.1%)
Jun 2008
-
-$16.68 M(+28.6%)
-$53.19 M(-17.2%)
Mar 2008
-
-$12.96 M(-205.7%)
-$64.24 M(-21.7%)
Dec 2007
-$82.07 M
$12.26 M(-134.2%)
-$82.07 M(-34.0%)
Sep 2007
-
-$35.81 M(+29.1%)
-$124.42 M(+9.9%)
DateAnnualQuarterlyTTM
Jun 2007
-
-$27.73 M(-9.9%)
-$113.16 M(+6.8%)
Mar 2007
-
-$30.79 M(+2.3%)
-$105.99 M(+13.9%)
Dec 2006
-$93.06 M(-166.5%)
-$30.09 M(+22.6%)
-$93.06 M(-158.1%)
Sep 2006
-
-$24.55 M(+19.4%)
$160.22 M(+3.8%)
Jun 2006
-
-$20.56 M(+15.1%)
$154.32 M(+5.3%)
Mar 2006
-
-$17.86 M(-108.0%)
$146.54 M(+4.7%)
Dec 2005
$139.93 M(+566.1%)
$223.19 M(-832.9%)
$139.93 M(-285.6%)
Sep 2005
-
-$30.45 M(+7.5%)
-$75.38 M(+49.2%)
Jun 2005
-
-$28.34 M(+15.7%)
-$50.53 M(+62.8%)
Mar 2005
-
-$24.48 M(-410.3%)
-$31.04 M(-247.8%)
Dec 2004
$21.01 M(-124.1%)
$7.89 M(-240.8%)
$21.01 M(+7070.0%)
Sep 2004
-
-$5.60 M(-36.7%)
$293.00 K(-101.8%)
Jun 2004
-
-$8.85 M(-132.1%)
-$16.15 M(-51.3%)
Mar 2004
-
$27.57 M(-314.9%)
-$33.18 M(-61.8%)
Dec 2003
-$87.05 M(-23.3%)
-$12.82 M(-41.8%)
-$86.84 M(-18.5%)
Sep 2003
-
-$22.05 M(-14.8%)
-$106.60 M(-6.9%)
Jun 2003
-
-$25.88 M(-0.8%)
-$114.56 M(-1.6%)
Mar 2003
-
-$26.09 M(-19.9%)
-$116.40 M(+2.6%)
Dec 2002
-$113.50 M(+42.6%)
-$32.58 M(+8.6%)
-$113.50 M(+4.4%)
Sep 2002
-
-$30.01 M(+8.2%)
-$108.70 M(+8.2%)
Jun 2002
-
-$27.72 M(+19.6%)
-$100.47 M(+12.4%)
Mar 2002
-
-$23.18 M(-16.5%)
-$89.41 M(+12.3%)
Dec 2001
-$79.61 M(+281.7%)
-$27.78 M(+27.6%)
-$79.61 M(+32.0%)
Sep 2001
-
-$21.77 M(+30.7%)
-$60.32 M(+14.1%)
Jun 2001
-
-$16.67 M(+24.5%)
-$52.87 M(+35.4%)
Mar 2001
-
-$13.38 M(+57.6%)
-$39.05 M(+17.5%)
Dec 2000
-$20.86 M(+2.2%)
-$8.49 M(-40.7%)
-$33.22 M(+35.4%)
Sep 2000
-
-$14.33 M(+405.2%)
-$24.52 M(+70.4%)
Jun 2000
-
-$2.84 M(-62.4%)
-$14.39 M(-24.5%)
Mar 2000
-
-$7.55 M(-3877.0%)
-$19.05 M(-10.1%)
Dec 1999
-$20.40 M(+114.7%)
$200.00 K(-104.8%)
-$21.20 M(-20.6%)
Sep 1999
-
-$4.20 M(-44.0%)
-$26.70 M(+10.3%)
Jun 1999
-
-$7.50 M(-22.7%)
-$24.20 M(+59.2%)
Mar 1999
-
-$9.70 M(+83.0%)
-$15.20 M(+60.0%)
Dec 1998
-$9.50 M(+2.2%)
-$5.30 M(+211.8%)
-$9.50 M(+17.3%)
Sep 1998
-
-$1.70 M(-213.3%)
-$8.10 M(+24.6%)
Jun 1998
-
$1.50 M(-137.5%)
-$6.50 M(-38.1%)
Mar 1998
-
-$4.00 M(+2.6%)
-$10.50 M(+11.7%)
Dec 1997
-$9.30 M(-17.0%)
-$3.90 M(+3800.0%)
-$9.40 M(+11.9%)
Sep 1997
-
-$100.00 K(-96.0%)
-$8.40 M(-25.0%)
Jun 1997
-
-$2.50 M(-13.8%)
-$11.20 M(+2.8%)
Mar 1997
-
-$2.90 M(0.0%)
-$10.90 M(-2.7%)
Dec 1996
-$11.20 M(+558.8%)
-$2.90 M(0.0%)
-$11.20 M(+15.5%)
Sep 1996
-
-$2.90 M(+31.8%)
-$9.70 M(+27.6%)
Jun 1996
-
-$2.20 M(-31.3%)
-$7.60 M(+46.2%)
Mar 1996
-
-$3.20 M(+128.6%)
-$5.20 M(+108.0%)
Dec 1995
-$1.70 M(-93.2%)
-$1.40 M(+75.0%)
-$2.50 M(-50.0%)
Sep 1995
-
-$800.00 K(-500.0%)
-$5.00 M(-26.5%)
Jun 1995
-
$200.00 K(-140.0%)
-$6.80 M(-57.5%)
Mar 1995
-
-$500.00 K(-87.2%)
-$16.00 M(-36.0%)
Dec 1994
-$25.00 M(-30.0%)
-$3.90 M(+50.0%)
-$25.00 M(-20.4%)
Sep 1994
-
-$2.60 M(-71.1%)
-$31.40 M(-15.8%)
Jun 1994
-
-$9.00 M(-5.3%)
-$37.30 M(-0.3%)
Mar 1994
-
-$9.50 M(-7.8%)
-$37.40 M(+2.7%)
Dec 1993
-$35.70 M(+119.0%)
-$10.30 M(+21.2%)
-$36.40 M(+15.2%)
Sep 1993
-
-$8.50 M(-6.6%)
-$31.60 M(+12.1%)
Jun 1993
-
-$9.10 M(+7.1%)
-$28.20 M(+27.6%)
Mar 1993
-
-$8.50 M(+54.5%)
-$22.10 M(+34.8%)
Dec 1992
-$16.30 M(+85.2%)
-$5.50 M(+7.8%)
-$16.40 M(+14.7%)
Sep 1992
-
-$5.10 M(+70.0%)
-$14.30 M(+24.3%)
Jun 1992
-
-$3.00 M(+7.1%)
-$11.50 M(+11.7%)
Mar 1992
-
-$2.80 M(-17.6%)
-$10.30 M(+87.3%)
Dec 1991
-$8.80 M(+193.3%)
-$3.40 M(+47.8%)
-$5.50 M(-39.6%)
Sep 1991
-
-$2.30 M(+27.8%)
-$9.10 M(+65.5%)
Jun 1991
-
-$1.80 M(-190.0%)
-$5.50 M(+120.0%)
Mar 1991
-
$2.00 M(-128.6%)
-$2.50 M(-24.2%)
Dec 1990
-$3.00 M
-$7.00 M(-638.5%)
-$3.30 M(-189.2%)
Sep 1990
-
$1.30 M(+8.3%)
$3.70 M(+54.2%)
Jun 1990
-
$1.20 M(0.0%)
$2.40 M(+100.0%)
Mar 1990
-
$1.20 M
$1.20 M

FAQ

  • What is Regeneron Pharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals annual EBITDA year-on-year change?
  • What is Regeneron Pharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals quarterly EBITDA year-on-year change?
  • What is Regeneron Pharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals TTM EBITDA year-on-year change?

What is Regeneron Pharmaceuticals annual EBITDA?

The current annual EBITDA of REGN is $5.32 B

What is the all time high annual EBITDA for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high annual EBITDA is $9.67 B

What is Regeneron Pharmaceuticals annual EBITDA year-on-year change?

Over the past year, REGN annual EBITDA has changed by +$624.70 M (+13.31%)

What is Regeneron Pharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of REGN is $1.09 B

What is the all time high quarterly EBITDA for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high quarterly EBITDA is $3.84 B

What is Regeneron Pharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, REGN quarterly EBITDA has changed by -$183.90 M (-14.38%)

What is Regeneron Pharmaceuticals TTM EBITDA?

The current TTM EBITDA of REGN is $5.32 B

What is the all time high TTM EBITDA for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high TTM EBITDA is $9.67 B

What is Regeneron Pharmaceuticals TTM EBITDA year-on-year change?

Over the past year, REGN TTM EBITDA has changed by +$624.70 M (+13.31%)